首页 | 短期课程 | 演讲者 | 赞助商/展览 | 海报 | 地点 | 目录下载(PDF) | 询问 | 报名注册

Premier Sponsor

Vivalis

View All Sponsors
View Media Partners

PEGS Summit 2012
(第8届PEGS/蛋白质
抗体工学高峰会议)

2012年4月30日-
2012年5月4日

Boston, 美国

the essential protein engineering summit

Choose your language
Japanese
Korean
English

目录下载(PDF)

2012 PEGS Brochure

2012 Final Brochure

产业会议汇总历

分析部门

蛋白质聚集与生物医药品的稳定性5月2日~3日


针对蛋白质聚集与其结果的研究与防止对策,在生物医学研究与医药品生产的领域上,为最重要的课题之一。本学会聚焦于「蛋白质聚集与生物医药品的稳定性」,对于关注蛋白质的特性描述和分析、蛋白质聚集所伴随而来的各种不良影响和免疫原性、蛋白质基础的治疗药物处方和制程开发等的研究人士,将针对此困难领域,呈现综合且符合现实的展望。

第1天 | 第2天

5月1日, 星期四


6:00-9:00 pm Recommended Dinner Short Course*


*Seperate registration required.


5月2日, 星期三

7:00 am Registration and Morning Coffee

ANALTYICAL METHODS: DETECTION AND CHARACTERIZATION

8:30 Chairperson's Opening Remarks

Vineet Kumar, Ph.D., Senior Research Scientist, Global Formulation Sciences, Parenterals, Abbott


» 8:40 Keynote Presentation

Causes and Control of Aggregation and High Viscosity in High Concentration Formulations

Thomas LaueThomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire

At high concentrations, the solution properties of protein formulations are dominated by the colloidal properties of the protein. These colloidal properties arise from weak forces between all of the solution species. The weak forces are electrostatic and electrodynamic in origin, with charge-charge interactions being the longest range and Van der Waals interactions the shortest range force. These weak forces give rise to solution nonideality, a readily measured quantity. Likewise, protein charge is a readily measured quantity that is important to the solution nonideality. This talk will cover: 1) Weak forces and concentrated solutions: definitions, nonideality and nonideality determination; 2) Measuring the charge on proteins: methods, accuracy and meaning; 3) Monoclonal antibody charge: an example of Nature's perverse sense of humor; 4) Charge and solution behavior: Charge may help or it may hurt solution properties; 5) The role of charge in aggregation; 6) The importance of protein dipole moment measurement.


Sponsored by
Malvern small
9:10 Combining Raman Spectroscopy and DLS for the Physico-Chemical Characterization of Protein Therapeutics

Neil LewisE. Neil Lewis, Ph.D., Chief Technology Officer, Malvern Instruments

The emergence of protein therapeutics has created a demand for new analytical methods because unlike small molecule pharmaceuticals their efficacy is also determined by their high order structure and conformation. Raman spectroscopy in combination with DLS can be used to measure these properties using small amounts of material under typical formulation conditions.

9:40 Characterization of Protein Aggregation in a Fusion Protein

James StrandJames Strand, Staff Research Associate, Analytical Develpment, Acceleron Pharma

The mechanisms behind non-native aggregation of recombinant Fc-fusion protein therapeutics from mammalian expression systems was studied specifically in relation to highly glycosylated proteins. Both chromatographic as well as higher order structural tools were used to define protein changes that may influence aggregation kinetics. In addition, the impact of glycosylation state on aggregation was also investigated.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

11:10 Sub-Visible Particle Detection in a High Concentration Protein Formulation

Mary Beth PelletierMary Beth Pelletier, Ph.D., Scientist, Analytical Technology, Biogen Idec

The development and qualification of a method for subvisible particle counting is described for a high concentration protein formulation. Challenges for this method include the concentration of the product and the prefilled syringe container-closure system, leading to the presence of silicon oil droplets in the samples. Significant development was carried out to ensure that the resulting method was robust, reproducible, and suitable for use in a QC environment.

11:40 Novel Mass Spec-Based Approaches to Characterize Aggregation and Association of Protein Therapeutics

Igor KaltashovIgor Kaltashov, Ph.D., Professor, Department of Chemistry, University of Massachusetts, Amherst

Traditionally, aggregation has been monitored using relatively low-resolution techniques that do not characterize the process at desired detail. An alternative is now provided by electrospray ionization mass spectrometry (ESI MS). We will discuss several recent developments that allow ESI MS to be used both in combination with classical tools and as a stand-alone technique for characterization of both soluble protein aggregates and products of ordered protein association.

Sponsored by
Quanta BioDesign
12:10 pm Luncheon Presentation I
Introducing dPEG®s as a New Paradigm in Addressing Protein Aggregation Issues

Paul D. Davis, Ph.D., President & CEO, Quanta BioDesign, Ltd.

Quanta has generated an abundance of data in working with proteins which suggests that its dPEG® technology could be a simple, yet flexible solution to solving or affecting many of the aggregation issues that are extant in biologics. In support, there are a number of key published references using the dPEG® technology to solve a wide range and variety of scenarios related to solubility, aggregation and elimination of non-specific binding. Data demonstrating these positive attributes of dPEG®s, as well as data on binding/activity and immunogenicity will be discussed.

12:40 Luncheon Presentation (Sponsorship Opportunity Available)

Understanding Mechanisms Of Aggregation: Extrinsic Factors And Excipients

1:30 Chairperson's Remarks

Thomas LaueThomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire




1:35 Mechanistic Links between Soluble Aggregate and Subvisible Particle Formation in Protein Therapeutics

Robert Simler, Ph.D., Staff Scientist, BioFormulations Development, Genzyme

Although a significant amount of recent work has focused on the quantification and characterization of subvisible particles, little is understood about the mechanism which links their formation to that of smaller, soluble aggregates. This talk will focus on agitation experiments designed to generate subvisible particles and soluble aggregates in an effort to identify a mechanistic relationship between the two higher order species. Practical consequences of this mechanism as they relate to formulation development will also be discussed.


» 2:05 Featured Presentation

High Concentration Protein Formulations: Complexity of the Stabilization and/or Destabilization Effects of Sugars/Polyols on Aggregation

Vineet KumarVineet Kumar, Ph.D., Senior Research Scientist, Global Formulation Sciences, Parenterals, Abbott

Sugars are widely used in low/high concentration protein formulations. In fact, more than 70% marketed protein formulations have sugars as stabilizers and/or tonicity modifiers. The talk will focus on the stabilization/destabilization effects of sugars and the strategies to select the best and the most useful poyol for the formulation. Audience will learn methods to appropriately select and/or deselect sugars especially for high concentration formulations.


2:35 Sponsored Presentations (Opportunities Available)

3:05 Refreshment Break in the Exhibit Hall with Poster Viewing

3:50 Problem Solving Breakout Discussions

4:50-6:00 Networking Reception in the Exhibit Hall with Poster Viewing



第1天 | 第2天


 

Cambridge Healthtech Institute  | 中文官方网站营运:Cambridge Healthtech Institute代理商 日商环球讯息有限公司